Foerster Robert, Eisele Christian, Bruckner Thomas, Bostel Tilman, Schlampp Ingmar, Wolf Robert, Debus Juergen, Rief Harald
Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Department of Medical Biometry, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany.
Radiat Oncol. 2015 Mar 7;10:62. doi: 10.1186/s13014-015-0368-x.
We designed this study to quantify the effects of radiotherapy (RT) on bone density as a local response in spinal bone metastases of women with breast cancer and, secondly, to establish bone density as an accurate and reproducible marker for assessment of local response to RT in spinal bone metastases.
We retrospectively assessed 135 osteolytic spinal metastases in 115 women with metastatic breast cancer treated at our department between January 2000 and January 2012. Primary endpoint was to compare bone density in the bone metastases before, 3 months after and 6 months after RT. Bone density was measured in Hounsfield units (HU) in computed tomography scans. We calculated mean values in HU and the standard deviation (SD) as a measurement of bone density before, 3 months and 6 months after RT. T-test was used for statistical analysis of difference in bone density as well as for univariate analysis of prognostic factors for difference in bone density 3 and 6 months after RT.
Mean bone density was 194.8 HU ± SD 123.0 at baseline. Bone density increased significantly by a mean of 145.8 HU ± SD 139.4 after 3 months (p = .0001) and by 250.3 HU ± SD 147.1 after 6 months (p < .0001). Women receiving bisphosphonates showed a tendency towards higher increase in bone density in the metastases after 3 months (152.6 HU ± SD 141.9 vs. 76.0 HU ± SD 86.1; p = .069) and pathological fractures before RT were associated with a significantly higher increase in bone density after 3 months (202.3 HU ± SD 161.9 vs. 130.3 HU ± SD 129.2; p = .013). Concomitant chemotherapy (ChT) or endocrine therapy (ET), hormone receptor status, performance score, applied overall RT dose and prescription of a surgical corset did not correlate with a difference in bone density after RT.
Bone density measurement in HU is a practicable and reproducible method for assessment of local RT response in osteolytic metastases in breast cancer. Our analysis demonstrated an excellent local response within metastases after palliative RT.
我们开展这项研究,旨在量化放射治疗(RT)对骨密度的影响,作为乳腺癌女性脊柱骨转移的局部反应,其次,将骨密度确立为评估脊柱骨转移对RT局部反应的准确且可重复的标志物。
我们回顾性评估了2000年1月至2012年1月间在我院接受治疗的115例转移性乳腺癌女性患者的135处溶骨性脊柱转移灶。主要终点是比较放疗前、放疗后3个月和放疗后6个月骨转移灶的骨密度。在计算机断层扫描中以亨氏单位(HU)测量骨密度。我们计算了放疗前、放疗后3个月和放疗后6个月HU的平均值和标准差(SD)作为骨密度的测量值。采用t检验对骨密度差异进行统计分析,并对放疗后3个月和6个月骨密度差异的预后因素进行单因素分析。
基线时平均骨密度为194.8 HU±标准差123.0。放疗后3个月骨密度显著增加,平均增加145.8 HU±标准差139.4(p = 0.0001),放疗后6个月增加250.3 HU±标准差147.1(p < 0.0001)。接受双膦酸盐治疗的女性在放疗后3个月转移灶骨密度增加趋势更高(152.6 HU±标准差141.9 vs. 76.0 HU±标准差86.1;p = 0.069),放疗前的病理性骨折与放疗后3个月骨密度显著更高的增加相关(202.3 HU±标准差161.9 vs. 130.3 HU±标准差129.2;p = 0.013)。同步化疗(ChT)或内分泌治疗(ET)、激素受体状态、体能评分、应用的总放疗剂量和手术束腰的处方与放疗后骨密度差异无关。
以HU测量骨密度是评估乳腺癌溶骨性转移灶局部放疗反应的一种可行且可重复的方法。我们的分析显示姑息性放疗后转移灶内有良好的局部反应。